1.98
1.02%
+0.02
アフターアワーズ:
1.98
Ocugen Inc (OCGN) 最新ニュース
Ocugen (NASDAQ:OCGN) Shares Gap Down to $1.96 - MarketBeat
MarketBeat
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
MarketWatch
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important ... - GlobeNewswire
GlobeNewswire
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment - MyChesCo
MyChesCo
Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals - MyChesCo
MyChesCo
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
MarketWatch
Ocugen completes second cohort dosing in Stargardt trial - Investing.com India
Investing.com India
Ocugen completes second cohort dosing in Stargardt trial - Investing.com
Investing.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen - GlobeNewswire
GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen - StreetInsider.com
StreetInsider.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen - Morningstar
Morningstar
Ocugen, Inc. (NASDAQ:OCGN) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
4 Analysts Assess Ocugen: What You Need To Know - Ocugen (NASDAQ:OCGN) - Benzinga
Benzinga
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical ... - Ocugen
Ocugen
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical ... - GlobeNewswire
GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
GlobeNewswire Inc.
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact ... - PR Newswire
PR Newswire
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials - Investing.com
Investing.com
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
MarketWatch
Ocugen: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
OCGN Stock Earnings: Ocugen Beats EPS for Q1 2024 - InvestorPlace
InvestorPlace
Ocugen Provides Business Update with First Quarter 2024 Financial Results | Ocugen, Inc. - Ocugen
Ocugen
Ocugen Provides Business Update with First Quarter 2024 Financial Results - GlobeNewswire
GlobeNewswire
Ocugen Provides Business Update with First Quarter 2024 Financial Results
GlobeNewswire Inc.
Ocugen: Q1 Earnings Snapshot | Business | thecourierexpress.com - The Courier-Express
The Courier-Express
Ocugen: Q1 Earnings Snapshot | National | wdrb.com - WDRB
WDRB
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
MarketWatch
Ocugen to Highlight Clinical Developments at Upcoming Life Sciences Conferences - MSN
MSN
Ocugen Announces Unique Dividend Strategy with Series C Preferred Stock - MSN
MSN
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
GlobeNewswire
Ocugen CEO to Highlight Gene Therapy Advances at Healthcare Equity Conference - MSN
MSN
Ocugen Announces Unique Dividend Strategy with Series C Preferred Stock - MyChesCo
MyChesCo
Implied Volatility Surging for Ocugen (OCGN) Stock Options - Yahoo News UK
Yahoo News UK
Ocugen to Highlight Clinical Developments at Upcoming Life Sciences Conferences - MyChesCo
MyChesCo
Ocugen (OCGN) Set to Announce Quarterly Earnings on Tuesday - Defense World
Defense World
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
MarketWatch
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline ... - PR Newswire
PR Newswire
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock - GlobeNewswire
GlobeNewswire
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
GlobeNewswire Inc.
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial ... - GlobeNewswire
GlobeNewswire
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial ... - GlobeNewswire
GlobeNewswire
Ocugen to Present at May 2024 Investor Conferences - WICZ
WICZ
Ocugen to Present at May 2024 Investor Conferences - GlobeNewswire
GlobeNewswire
Ocugen to Present at May 2024 Investor Conferences - Yahoo Finance
Yahoo Finance
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class ... - AccessWire
AccessWire
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
MarketWatch
ROSEN, A RANKED AND LEADING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important ... - The Globe and Mail
The Globe and Mail
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
MarketWatch
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm - Barron's
Barron's
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen - GlobeNewswire
GlobeNewswire
大文字化:
|
ボリューム (24 時間):